In summary, we confirmed that both statins activate apoptosis in NSCLC cell lines in vitro. Co-administration of pitavastatin with erlotinib synergistically increased pitavastatin cytotoxicity, especially in K-Ras mutated cell lines. Nevertheless, the effects were weaker in MET-driven EGFR-TKI resistance. This evidence concerns the gene KRAS and non-small cell lung carcinoma.